Ann: 2 for 9 rights issue - prospectus-OIL.AX, page-10

Not much to go on, it's true. The low profile of the Zeiss collaboration in the assignment of funding is both reassuring and a bit scary: it seems like it's now up to Zeiss to move things along, which means limited funding/work from Optiscan is now needed but also means we have little control over how things proceed (the past bottlenecks seem to have been largely technical, hence our problem, I expect the future ones to be in product finalisation and marketing and sales). There's not much to be said about CellLive; I assume information about sales will be in the annual report. I was told they only need to sell around 1.5 systems a month to cover operating costs, so even a small pickup here might be significant. And the other products are still in the lab.